TY  - JOUR
AU  - Bužančić, Iva
AU  - Držaić, Margita
AU  - Kummer, Ingrid
AU  - Ortner Hadžiabdić, Maja
AU  - Brkić, Jovana
AU  - Fialová, Daniela
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5621
AB  - Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-024-56780-1, published online 14 March 2024 The original version of this Article contained an error in the Funding section. “All the research work was funded by the EuroAgeism H2020 project (ESR7 project), supported by the European Union research and innovation program under the Grant Agreement of the Marie Skłodowska-Curie Foundation Number MSCF-ITN-764632. Research works of Assoc. Prof. Daniela Fialová, PharmD, Ph.D. and members of her research team were supported by the Grants: InoMed, Reg. No CZ.02.1.01/0.0/0.0/18_069/0010046, the European Horizon 2020 I-CARE4OLD Grant No 965341, START/MED/093 EN.02.2.69/0.0/0.0/19_073/0016935, SVV 260 551 Grant and Cooperatio research program of the Faculty of Pharmacy, Charles University (Research Unit: “Ageing, Polypharmacotherapy and Changes in Therapeutic Value of Drugs in the Aged’’, KSKF-I.), and NETPHARM project CZ.02.01.01/00/22_008/0004607. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.” now reads: “Publication of this work was supported by the I-CARE4OLD project that has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No. 96534. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. More information on the I-CARE4OLD project can be found at http://www.icare4old.eu and https://cordis.europa.eu/project/id/965341. Except secondary analyses and works on the publication, data collection and teamwork were funded also by the EuroAgeism H2020 project (ESR7 project), supported by the European Union research and innovation program under the Grant Agreement of the Marie Skłodowska-Curie Foundation Number MSCF-ITN-764632. Research works of Assoc. Prof. Daniela Fialová, PharmD, Ph.D. and members of her research team were supported by grants: START/MED/093 EN.02.2.69/0.0/0.0/19_073/0016935, SVV 260 551, Cooperatio research program of the Faculty of Pharmacy, Charles University (Research Unit: “Ageing, Polypharmacotherapy and Changes in Terapeutic Value of Drugs in the Aged’’, KSKF-I.), and NETPHARM project CZ.02.01.01/00/22_008/0004607.” The original Article has been corrected.
PB  - Nature Research
T2  - Scientific Reports
T1  - Correction to: Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment (Scientific Reports, (2024), 14, 1, (6235), 10.1038/s41598-024-56780-1)
VL  - 14
IS  - 1
DO  - 10.1038/s41598-024-60073-y
ER  - 

@article{
author = "Bužančić, Iva and Držaić, Margita and Kummer, Ingrid and Ortner Hadžiabdić, Maja and Brkić, Jovana and Fialová, Daniela",
year = "2024",
abstract = "Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-024-56780-1, published online 14 March 2024 The original version of this Article contained an error in the Funding section. “All the research work was funded by the EuroAgeism H2020 project (ESR7 project), supported by the European Union research and innovation program under the Grant Agreement of the Marie Skłodowska-Curie Foundation Number MSCF-ITN-764632. Research works of Assoc. Prof. Daniela Fialová, PharmD, Ph.D. and members of her research team were supported by the Grants: InoMed, Reg. No CZ.02.1.01/0.0/0.0/18_069/0010046, the European Horizon 2020 I-CARE4OLD Grant No 965341, START/MED/093 EN.02.2.69/0.0/0.0/19_073/0016935, SVV 260 551 Grant and Cooperatio research program of the Faculty of Pharmacy, Charles University (Research Unit: “Ageing, Polypharmacotherapy and Changes in Therapeutic Value of Drugs in the Aged’’, KSKF-I.), and NETPHARM project CZ.02.01.01/00/22_008/0004607. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.” now reads: “Publication of this work was supported by the I-CARE4OLD project that has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No. 96534. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. More information on the I-CARE4OLD project can be found at http://www.icare4old.eu and https://cordis.europa.eu/project/id/965341. Except secondary analyses and works on the publication, data collection and teamwork were funded also by the EuroAgeism H2020 project (ESR7 project), supported by the European Union research and innovation program under the Grant Agreement of the Marie Skłodowska-Curie Foundation Number MSCF-ITN-764632. Research works of Assoc. Prof. Daniela Fialová, PharmD, Ph.D. and members of her research team were supported by grants: START/MED/093 EN.02.2.69/0.0/0.0/19_073/0016935, SVV 260 551, Cooperatio research program of the Faculty of Pharmacy, Charles University (Research Unit: “Ageing, Polypharmacotherapy and Changes in Terapeutic Value of Drugs in the Aged’’, KSKF-I.), and NETPHARM project CZ.02.01.01/00/22_008/0004607.” The original Article has been corrected.",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "Correction to: Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment (Scientific Reports, (2024), 14, 1, (6235), 10.1038/s41598-024-56780-1)",
volume = "14",
number = "1",
doi = "10.1038/s41598-024-60073-y"
}

Bužančić, I., Držaić, M., Kummer, I., Ortner Hadžiabdić, M., Brkić, J.,& Fialová, D.. (2024). Correction to: Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment (Scientific Reports, (2024), 14, 1, (6235), 10.1038/s41598-024-56780-1). in Scientific Reports
Nature Research., 14(1).
https://doi.org/10.1038/s41598-024-60073-y

Bužančić I, Držaić M, Kummer I, Ortner Hadžiabdić M, Brkić J, Fialová D. Correction to: Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment (Scientific Reports, (2024), 14, 1, (6235), 10.1038/s41598-024-56780-1). in Scientific Reports. 2024;14(1).
doi:10.1038/s41598-024-60073-y .

Bužančić, Iva, Držaić, Margita, Kummer, Ingrid, Ortner Hadžiabdić, Maja, Brkić, Jovana, Fialová, Daniela, "Correction to: Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment (Scientific Reports, (2024), 14, 1, (6235), 10.1038/s41598-024-56780-1)" in Scientific Reports, 14, no. 1 (2024),
https://doi.org/10.1038/s41598-024-60073-y . .

TY  - JOUR
AU  - Bužančić, Iva
AU  - Držaić, Margita
AU  - Kummer, Ingrid
AU  - Ortner Hadžiabdić, Maja
AU  - Brkić, Jovana
AU  - Fialová, Daniela
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5571
AB  - Pharmacist’s geriatric assessment can provide valuable insights into potential deprescribing targets, while including important information on various health-related domains. Data collected from a geriatric assessment questionnaire, for 388 patients, from the Croatian cohort of the EuroAgeism H2020 ESR 7 international project, along with guideline-based deprescribing criteria, were used to analyse potentially inappropriate prescribing of four medication groups (benzodiazepines (BZN), proton pump inhibitors (PPI), opioids, and non-steroidal anti-inflammatory drugs (NSAID)), and to assess the deprescribing potential. Binary logistic regression was used to explore the effects of age, gender, number of medicines and diagnoses, self-reported health, frailty score, and healthcare utilization on the likelihood of needing deprescribing. More than half of participants (n = 216, 55.2%) are candidates for deprescribing, with 31.1% of PPI, 74.8% of NSAID, 75% of opioid, and 96.1% of BZN users meeting at least one criterion. Most common criteria for deprescribing were inappropriately long use and safety concerns. Women (aOR = 2.58; p < 0.001), those reporting poor self-reported health (aOR = 5.14; p < 0.001), and those exposed to polypharmacy (aOR = 1.29; p < 0.001) had higher odds of needing to have medicines deprescribed. The high rate of deprescribing potential warrants prompt action to increase patient safety and decrease polypharmacy. Pharmacist’s geriatric assessment and deprescribing-focused medication review could be used to lead a personalised approach.
PB  - Nature Research
T2  - Scientific Reports
T1  - Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment
VL  - 14
IS  - 1
SP  - 6235
DO  - 10.1038/s41598-024-56780-1
ER  - 

@article{
author = "Bužančić, Iva and Držaić, Margita and Kummer, Ingrid and Ortner Hadžiabdić, Maja and Brkić, Jovana and Fialová, Daniela",
year = "2024",
abstract = "Pharmacist’s geriatric assessment can provide valuable insights into potential deprescribing targets, while including important information on various health-related domains. Data collected from a geriatric assessment questionnaire, for 388 patients, from the Croatian cohort of the EuroAgeism H2020 ESR 7 international project, along with guideline-based deprescribing criteria, were used to analyse potentially inappropriate prescribing of four medication groups (benzodiazepines (BZN), proton pump inhibitors (PPI), opioids, and non-steroidal anti-inflammatory drugs (NSAID)), and to assess the deprescribing potential. Binary logistic regression was used to explore the effects of age, gender, number of medicines and diagnoses, self-reported health, frailty score, and healthcare utilization on the likelihood of needing deprescribing. More than half of participants (n = 216, 55.2%) are candidates for deprescribing, with 31.1% of PPI, 74.8% of NSAID, 75% of opioid, and 96.1% of BZN users meeting at least one criterion. Most common criteria for deprescribing were inappropriately long use and safety concerns. Women (aOR = 2.58; p < 0.001), those reporting poor self-reported health (aOR = 5.14; p < 0.001), and those exposed to polypharmacy (aOR = 1.29; p < 0.001) had higher odds of needing to have medicines deprescribed. The high rate of deprescribing potential warrants prompt action to increase patient safety and decrease polypharmacy. Pharmacist’s geriatric assessment and deprescribing-focused medication review could be used to lead a personalised approach.",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment",
volume = "14",
number = "1",
pages = "6235",
doi = "10.1038/s41598-024-56780-1"
}

Bužančić, I., Držaić, M., Kummer, I., Ortner Hadžiabdić, M., Brkić, J.,& Fialová, D.. (2024). Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment. in Scientific Reports
Nature Research., 14(1), 6235.
https://doi.org/10.1038/s41598-024-56780-1

Bužančić I, Držaić M, Kummer I, Ortner Hadžiabdić M, Brkić J, Fialová D. Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment. in Scientific Reports. 2024;14(1):6235.
doi:10.1038/s41598-024-56780-1 .

Bužančić, Iva, Držaić, Margita, Kummer, Ingrid, Ortner Hadžiabdić, Maja, Brkić, Jovana, Fialová, Daniela, "Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment" in Scientific Reports, 14, no. 1 (2024):6235,
https://doi.org/10.1038/s41598-024-56780-1 . .

TY  - JOUR
AU  - Bužančić, Iva
AU  - Belec, Dora
AU  - Držaić, Margita
AU  - Kummer, Ingrid
AU  - Brkić, Jovana
AU  - Fialová, Daniela
AU  - Ortner Hadžiabdić, Maja
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5344
AB  - Aims: The aim of this study was to compare the clinical decision-making for benzodiazepine deprescribing between a healthcare provider (HCP) and an artificial intelligence (AI) chatbot GPT4 (ChatGPT-4). Methods: We analysed real-world data from a Croatian cohort of community-dwelling benzodiazepine patients (n = 154) within the EuroAgeism H2020 ESR 7 project. HCPs evaluated the data using pre-established deprescribing criteria to assess benzodiazepine discontinuation potential. The research team devised and tested AI prompts to ensure consistency with HCP judgements. An independent researcher employed ChatGPT-4 with predetermined prompts to simulate clinical decisions for each patient case. Data derived from human-HCP and ChatGPT-4 decisions were compared for agreement rates and Cohen's kappa. 
Results : Both HPC and ChatGPT identified patients for benzodiazepine deprescribing (96.1% and 89.6%, respectively), showing an agreement rate of 95% (κ=.200,P=.012). Agreement on four deprescribing criteria ranged from 74.7% to 91.3%(lack of indicationκ=.352,P< .001; prolonged useκ=.088,P=.280; safety concernsκ=.123,P=.006; incorrect dosageκ=.264,P=.001). Important limitationsof GPT-4 responses were identified, including 22.1% ambiguous outputs, genericanswers and inaccuracies, posing inappropriate decision-making risks.Conclusions : While AI-HCP agreement is substantial, sole AI reliance poses a risk forunsuitable clinical decision-making. This study's findings reveal both strengths andareas for enhancement of ChatGPT-4 in the deprescribing recommendations within areal-world sample. Our study underscores the need for additional research on chatbot functionality in patient therapy decision-making, further fostering the advance-ment of AI for optimal performance.
PB  - John Wiley and Sons Inc
T2  - British Journal of Clinical Pharmacology
T1  - Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach
VL  - 90
IS  - 3
SP  - 662
EP  - 674
DO  - 10.1111/bcp.15963
ER  - 

@article{
author = "Bužančić, Iva and Belec, Dora and Držaić, Margita and Kummer, Ingrid and Brkić, Jovana and Fialová, Daniela and Ortner Hadžiabdić, Maja",
year = "2024",
abstract = "Aims: The aim of this study was to compare the clinical decision-making for benzodiazepine deprescribing between a healthcare provider (HCP) and an artificial intelligence (AI) chatbot GPT4 (ChatGPT-4). Methods: We analysed real-world data from a Croatian cohort of community-dwelling benzodiazepine patients (n = 154) within the EuroAgeism H2020 ESR 7 project. HCPs evaluated the data using pre-established deprescribing criteria to assess benzodiazepine discontinuation potential. The research team devised and tested AI prompts to ensure consistency with HCP judgements. An independent researcher employed ChatGPT-4 with predetermined prompts to simulate clinical decisions for each patient case. Data derived from human-HCP and ChatGPT-4 decisions were compared for agreement rates and Cohen's kappa. 
Results : Both HPC and ChatGPT identified patients for benzodiazepine deprescribing (96.1% and 89.6%, respectively), showing an agreement rate of 95% (κ=.200,P=.012). Agreement on four deprescribing criteria ranged from 74.7% to 91.3%(lack of indicationκ=.352,P< .001; prolonged useκ=.088,P=.280; safety concernsκ=.123,P=.006; incorrect dosageκ=.264,P=.001). Important limitationsof GPT-4 responses were identified, including 22.1% ambiguous outputs, genericanswers and inaccuracies, posing inappropriate decision-making risks.Conclusions : While AI-HCP agreement is substantial, sole AI reliance poses a risk forunsuitable clinical decision-making. This study's findings reveal both strengths andareas for enhancement of ChatGPT-4 in the deprescribing recommendations within areal-world sample. Our study underscores the need for additional research on chatbot functionality in patient therapy decision-making, further fostering the advance-ment of AI for optimal performance.",
publisher = "John Wiley and Sons Inc",
journal = "British Journal of Clinical Pharmacology",
title = "Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach",
volume = "90",
number = "3",
pages = "662-674",
doi = "10.1111/bcp.15963"
}

Bužančić, I., Belec, D., Držaić, M., Kummer, I., Brkić, J., Fialová, D.,& Ortner Hadžiabdić, M.. (2024). Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach. in British Journal of Clinical Pharmacology
John Wiley and Sons Inc., 90(3), 662-674.
https://doi.org/10.1111/bcp.15963

Bužančić I, Belec D, Držaić M, Kummer I, Brkić J, Fialová D, Ortner Hadžiabdić M. Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach. in British Journal of Clinical Pharmacology. 2024;90(3):662-674.
doi:10.1111/bcp.15963 .

Bužančić, Iva, Belec, Dora, Držaić, Margita, Kummer, Ingrid, Brkić, Jovana, Fialová, Daniela, Ortner Hadžiabdić, Maja, "Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach" in British Journal of Clinical Pharmacology, 90, no. 3 (2024):662-674,
https://doi.org/10.1111/bcp.15963 . .